{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T23:23:46Z","timestamp":1791156226004,"version":"4.1.0"},"reference-count":56,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T00:00:00Z","timestamp":1699056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To evaluate the real-world performance and reference intervals of the Binding Site Freelite serum free light chain (SFLC) assay (Thermo Fisher Scientific), a global standard for diagnosis, prognostication, and response assessment for monoclonal gammopathies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>An informatics-based approach was used to retrospectively evaluate concordance between SFLC and the orthogonal Sebia HYDRASYS immunofixation assay results in a large clinical data set consecutively reported between 2010 and 2020.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among patients with monoclonal-negative results by both SFLC and Sebia HYDRASYS immunofixation assays, 25% (1226\/5057) had \u03ba\/\u03bb ratios (KLRs) outside the manufacturer-defined and International Myeloma Working Group\u2013cited normal reference interval of 0.26 to 1.65. These results were consistent over the study period and were not affected by sex, age, impaired kidney function, or assay antisera lot variation. Assay drift, in addition to other potential factors, affected the KLR distribution. Using International Statistical Classification of Diseases (ICD) codes, kidney function data, and the central 95% of KLR values generated on the Optilite platform (Thermo Fisher Scientific), we derived a new reference interval of 0.67 to 2.13, reducing the KLR false-positive rate to 8%. However, normal KLR persisted among 16% (14\/85) of samples with free \u03bb chains by immunofixation, warranting caution during interpretation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our analysis indicated that revision of Freelite SFLC reference intervals improves assay interpretation and should prompt reconsideration of Freelite reference intervals worldwide.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajcp\/aqad137","type":"journal-article","created":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T04:47:32Z","timestamp":1699418852000},"page":"216-231","source":"Crossref","is-referenced-by-count":5,"title":["Data analytics improves the diagnostic accuracy of serum free light chain results for detecting monoclonal gammopathy"],"prefix":"10.1093","volume":"161","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2736-3341","authenticated-orcid":false,"given":"Rebecca S","family":"Treger","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, University of Washington , Seattle, WA , US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4266-561X","authenticated-orcid":false,"given":"Patrick C","family":"Mathias","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, University of Washington , Seattle, WA , US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J","family":"Cowan","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, University of Washington , Seattle, WA , US"},{"name":"Clinical Research Division, Fred Hutch Cancer Center , Seattle, WA , US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian","family":"Green","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, University of Washington , Seattle, WA , US"},{"name":"Clinical Research Division, Fred Hutch Cancer Center , Seattle, WA , US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Hutchinson","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, University of Washington , Seattle, WA , US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Bryan","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, University of Washington , Seattle, WA , US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anu","family":"Chaudhary","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, University of Washington , Seattle, WA , US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1705-0103","authenticated-orcid":false,"given":"Susan L","family":"Fink","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, University of Washington , Seattle, WA , US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8304-6957","authenticated-orcid":false,"given":"Mark H","family":"Wener","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, University of Washington , Seattle, WA , US"},{"name":"Division of Rheumatology, Department of Medicine, University of Washington , Seattle, WA , US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5330-9464","authenticated-orcid":false,"given":"Chihiro","family":"Morishima","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, University of Washington , Seattle, WA , US"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,11,4]]},"reference":[{"issue":"9","key":"2024030111170772300_CIT0001","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/clinchem\/48.9.1437","article-title":"Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains","volume":"48","author":"Katzmann","year":"2002","journal-title":"Clin Chem."},{"key":"2024030111170772300_CIT0002","first-page":"8706","article-title":"Serum free light chain analysis and urine immunofixation electrophoresis in patients with multiple myeloma","volume-title":"Clin Cancer Res.","author":"Nowrousian","year":"2005"},{"key":"2024030111170772300_CIT0003","first-page":"489","article-title":"Serum test for assessment of patients with Bence Jones myeloma","volume-title":"Lancet.","author":"Bradwell","year":"2003"},{"key":"2024030111170772300_CIT0004","first-page":"356","article-title":"Comparison of serum free light chain and urine electrophoresis for the detection of the light chain component of monoclonal immunoglobulins in light chain and intact immunoglobulin multiple myeloma","volume-title":"Haematologica.","author":"Dejoie","year":"2016"},{"key":"2024030111170772300_CIT0005","first-page":"e328","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume-title":"Lancet Oncol.","author":"Kumar","year":"2016"},{"key":"2024030111170772300_CIT0006","first-page":"848","article-title":"Immunoglobulin light chain amyloidosis: 2020 update on diagnosis, prognosis, and treatment","volume-title":"Am J Hematol.","author":"Gertz","year":"2020"},{"key":"2024030111170772300_CIT0007","first-page":"812","article-title":"Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance","volume-title":"Blood.","author":"Rajkumar","year":"2005"},{"key":"2024030111170772300_CIT0008","first-page":"1979","article-title":"Immunoglobulin free light chains and solitary plasmacytoma of bone","volume-title":"Blood.","author":"Dingli","year":"2006"},{"key":"2024030111170772300_CIT0009","first-page":"102","article-title":"International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)","volume-title":"Blood Cancer J.","author":"Mateos","year":"2020"},{"key":"2024030111170772300_CIT0010","first-page":"215","article-title":"International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders","volume-title":"Leukemia.","author":"Dispenzieri","year":"2009"},{"key":"2024030111170772300_CIT0011","first-page":"4541","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume-title":"J Clin Oncol.","author":"Palladini","year":"2012"},{"key":"2024030111170772300_CIT0012","article-title":"RStudio: Integrated Development for R","author":"RStudio Team","year":"2020"},{"key":"2024030111170772300_CIT0013","article-title":"R: A language and environment for statistical computing","author":"R Core Team","year":"2019"},{"key":"2024030111170772300_CIT0014","first-page":"1686","article-title":"Welcome to the Tidyverse","volume-title":"J Open Source Software","author":"Wickham","year":"2019"},{"key":"2024030111170772300_CIT0015","first-page":"1","article-title":"Dates and times made easy with lubridate","volume-title":"J Statistical Software","author":"Grolemund","year":"2011"},{"key":"2024030111170772300_CIT0016","article-title":"janitor: simple tools for examining and cleaning dirty data","author":"Firke","year":"2021"},{"key":"2024030111170772300_CIT0017","article-title":"HDInterval: highest (posterior) density intervals","author":"Meredith","year":"2020"},{"key":"2024030111170772300_CIT0018","article-title":"confintr: Confidence Intervals","author":"Mayer","year":"2022"},{"key":"2024030111170772300_CIT0019","first-page":"16023","article-title":"refineR: a novel algorithm for reference interval estimation from real-world data","volume-title":"Sci Rep.","author":"Ammer","year":"2021"},{"key":"2024030111170772300_CIT0020","volume-title":"referenceIntervals: reference intervals","author":"Finnegan","year":"2020"},{"key":"2024030111170772300_CIT0021","article-title":"cowplot: streamlined plot theme and plot annotations for \u201cggplot2.\u201d","author":"Wilke","year":"2020"},{"key":"2024030111170772300_CIT0022","volume-title":"gridExtra: miscellaneous functions for \u201cgrid\u201d graphics","author":"Auguie","year":"2017"},{"key":"2024030111170772300_CIT0023","first-page":"16","article-title":"Calculating estimated glomerular filtration rate without the race correction factor: observations at a large academic medical system","volume-title":"Clin Chim Acta.","author":"Shi","year":"2021"},{"key":"2024030111170772300_CIT0024","first-page":"312","article-title":"Evaluation of a new free light chain ELISA assay: bringing coherence with electrophoretic methods","volume-title":"Clin Chem Lab Med.","author":"Jacobs","year":"2018"},{"key":"2024030111170772300_CIT0025","first-page":"161","article-title":"Evaluation of the new Sebia free light chain assay using the AP22 ELITE instrument","volume-title":"Clin Chim Acta.","author":"Lutteri","year":"2018"},{"key":"2024030111170772300_CIT0026","first-page":"613","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases","volume-title":"J Clin Epidemiol.","author":"Deyo","year":"1992"},{"key":"2024030111170772300_CIT0027","first-page":"117","article-title":"Development of a research tool to document self-reported chronic conditions in primary care","volume-title":"J Comorb","author":"Fortin","year":"2017"},{"key":"2024030111170772300_CIT0028","article-title":"multimorbidity","author":"Bensken","year":"2023"},{"key":"2024030111170772300_CIT0029","first-page":"1691","article-title":"Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic\/racial groups: support for genetic factors in pathogenesis","volume-title":"Leukemia.","author":"Landgren","year":"2009"},{"key":"2024030111170772300_CIT0030","first-page":"21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume-title":"Mayo Clin Proc.","author":"Kyle","year":"2003"},{"key":"2024030111170772300_CIT0031","first-page":"1046","article-title":"Epidemiology of AL amyloidosis: a real-world study using US claims data","volume-title":"Blood Adv.","author":"Quock","year":"2018"},{"key":"2024030111170772300_CIT0032","first-page":"1684","article-title":"Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease","volume-title":"Clin J Am Soc Nephrol.","author":"Hutchison","year":"2008"},{"key":"2024030111170772300_CIT0033","first-page":"11","article-title":"Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure","volume-title":"BMC Nephrol.","author":"Hutchison","year":"2008"},{"key":"2024030111170772300_CIT0034","first-page":"111","article-title":"The renal range of the \u03ba\/\u03bb sFLC ratio: best strategy to evaluate multiple myeloma in patients with chronic kidney disease","volume-title":"BMC Nephrol.","author":"Molina-Andujar","year":"2020"},{"key":"2024030111170772300_CIT0035","first-page":"805","article-title":"Serum free light chain measurements move to center stage","volume-title":"Clin Chem.","author":"Bradwell","year":"2005"},{"key":"2024030111170772300_CIT0036","first-page":"133","article-title":"Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: results of the iStopMM study","volume-title":"Blood Cancer J.","author":"Long","year":"2022"},{"key":"2024030111170772300_CIT0037","first-page":"1411","article-title":"Free light chain assay drift: potential for misdiagnosis","volume-title":"J Appl Lab Med.","author":"Murray","year":"2020"},{"key":"2024030111170772300_CIT0038","first-page":"207","article-title":"Serum free light chain assay and \u03ba\/\u03bb ratio performance in patients without monoclonal gammopathies: high false-positive rate","volume-title":"Am J Clin Pathol.","author":"Singh","year":"2016"},{"key":"2024030111170772300_CIT0039","first-page":"2303","article-title":"Evaluation of the N Latex free light chain assay in the diagnosis and monitoring of AL amyloidosis","volume-title":"Clin Chem Lab Med.","author":"Mollee","year":"2013"},{"key":"2024030111170772300_CIT0040","first-page":"221","article-title":"Different immunoreactivity of monomers and dimers makes automated free light chains assays not equivalent","volume-title":"Clin Chem Lab Med.","author":"Caponi","year":"2018"},{"key":"2024030111170772300_CIT0041","first-page":"73","article-title":"Inter-assay variability in automated serum free light chain assays and their use in the clinical laboratory","volume-title":"Crit Rev Clin Lab Sci.","author":"Caponi","year":"2020"},{"key":"2024030111170772300_CIT0042","first-page":"1","article-title":"Development of a highly-sensitive multi-plex assay using monoclonal antibodies for the simultaneous measurement of kappa and lambda immunoglobulin free light chains in serum and urine","volume-title":"J Immunol Methods.","author":"Campbell","year":"2013"},{"key":"2024030111170772300_CIT0043","first-page":"1005","article-title":"Measurement of free light chains with assays based on monoclonal antibodies","volume-title":"Clin Chem Lab Med","author":"Velthuis","year":"2016"},{"key":"2024030111170772300_CIT0044","first-page":"772","article-title":"The utility of MASS-FIX to detect and monitor monoclonal proteins in the clinic","volume-title":"Am J Hematol.","author":"Milani","year":"2017"},{"key":"2024030111170772300_CIT0045","first-page":"100","article-title":"Reference intervals and diagnostic ranges for serum free \u03ba and free \u03bb immunoglobulin light chains vary by instrument platform: implications for classification of patient results in a multi-center study","volume-title":"Clin Biochem.","author":"Cotten","year":"2018"},{"key":"2024030111170772300_CIT0046","first-page":"114","article-title":"Serum free light chain assay: shift toward a higher \u03ba\/\u03bb ratio","volume-title":"J Appl Lab Med.","author":"Rindlisbacher","year":"2020"},{"key":"2024030111170772300_CIT0047","first-page":"54","article-title":"Serum free light chain reference intervals in an Optilite and their influence on clinical guidelines","volume-title":"Clin Biochem.","author":"Morales-Garcia","year":"2021"},{"key":"2024030111170772300_CIT0048","first-page":"742","article-title":"Kappa free light chain drift prompts the need for a new upper limit of normal free light chain ratio to avoid an epidemic of kappa light chain monoclonal gammopathy of undermined significance","volume-title":"J Appl Lab Med.","author":"Rozenova","year":"2023"},{"key":"2024030111170772300_CIT0049","first-page":"5501","article-title":"Racial disparities in incidence and outcome in multiple myeloma: a population-based study","volume-title":"Blood.","author":"Waxman","year":"2010"},{"key":"2024030111170772300_CIT0050","first-page":"855","article-title":"Chronic kidney disease in African Americans: puzzle pieces are falling into place","volume-title":"Cleve Clin J Med.","author":"Nally","year":"2017"},{"key":"2024030111170772300_CIT0051","first-page":"719","article-title":"Accuracy of race, ethnicity, and language preference in an electronic health record","volume-title":"J Gen Intern Med.","author":"Klinger","year":"2015"},{"key":"2024030111170772300_CIT0052","first-page":"2070","article-title":"Race and genetic ancestry in medicine","volume-title":"N Engl J Med.","author":"Enea","year":"2021"},{"key":"2024030111170772300_CIT0053","first-page":"152","article-title":"In response to: Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: results of the iStopMM study","volume-title":"Blood Cancer J.","author":"Minnema","year":"2022"},{"key":"2024030111170772300_CIT0054","first-page":"20","article-title":"Indirect methods for reference interval determination\u2014review and recommendations","volume-title":"Clin Chem Lab Med.","author":"Jones","year":"2018"},{"key":"2024030111170772300_CIT0055","first-page":"4856","article-title":"Prognostic impact of serum free light chain ratio normalization in patients with multiple myeloma treated within the GMMG-MM5 trial","volume-title":"Cancers (Basel)","author":"Klein","year":"2021"},{"key":"2024030111170772300_CIT0056","first-page":"134","article-title":"Normalization of free light chain kappa\/lambda ratio is a robust prognostic indicator of favorable outcome in patients with multiple myeloma","volume-title":"Eur J Haematol.","author":"Iwama","year":"2013"}],"container-title":["American Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/161\/3\/216\/56798467\/aqad137.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/161\/3\/216\/56798467\/aqad137.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T11:19:36Z","timestamp":1709291976000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajcp\/article\/161\/3\/216\/7344338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,4]]},"references-count":56,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,11,4]]},"published-print":{"date-parts":[[2024,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ajcp\/aqad137","relation":{},"ISSN":["0002-9173","1943-7722"],"issn-type":[{"value":"0002-9173","type":"print"},{"value":"1943-7722","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,3,1]]},"published":{"date-parts":[[2023,11,4]]}}}